Page 1

Interim report January - March 2021 Good growth in the first quarter Significant events during the first quarter Net sales increased by 9 % ( 20 % adjusted for currency changes ) to SEK 171 m ( 158 ) . . EBITDA margin was 28 % ( 19 % ) . First deliveries related to the Pan - European agreement with Perrigo , which includes the launch of Probi's ClinBac ™ concept in 14 European countries . Strategic partnership with the Chinese pharmaceutical company China National Pharmaceutical Foreign Trade Corporation ( Sinopharm Foreign Trade ) a wholly owned subsidiary of China National Pharmaceutical Group Corporation ( Sinopharm ) for the launch of three of Probi's ClinBac ™ concepts in China . New bone health study in collaboration with La Trobe University in Australia to investigate the effects of ProbiⓇ Osteo on Australian women . SEK 171 m Net sales 28 % EBITDA margin Financial overview Jan - Mar Full - year SEK M 2021 2020 RTM 2020 Net sales 171.3 157.8 730.7 717.2 Growth , % 8.6 % 14.2 % 1.9 % 14.5 % Currency adjusted growth , % 20.3 % 11.2 % 7.1 % 16.9 % Gross margin , % 43.4 % 39.0 % 44.2 % 43.2 % EBITDA 47.1 29.9 213.7 196.5 EBITDA margin , % 27.5 % 18.9 % 29.3 % 27.4 % Operating profit ( EBIT ) 30.1 11.0 142.8 123.7 EBIT margin , % 17.6 % 7.0 % 19.5 % 17.2 % Net income 22.6 10.7 104.7 92.7 Earnings per share before and after dilution , SEK 1.99 0.94 9.19 8.14 See note 5 for definitions of ratios not defined according to IFRS This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation . The Information was submitted for publication , through the agency of the CEO and CFO , on April 23 , 2021 at 08:00 CET . This is a translation of the Swedish version of the interim report . When in doubt , the Swedish wording prevails . þ probi first in probiotics